High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma
1998

High Expression of Immunotherapy Candidate Proteins in Uveal Melanoma

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): TJ de Vries, D Trancilkova, DJ Ruiter, GNP van Muijen

Primary Institution: University Hospital, Nijmegen, The Netherlands; Cancer Research Institute, Slovak Academy of Sciences

Hypothesis

Do uveal melanoma lesions express immunotherapy candidate proteins gp100, MART-1, tyrosinase, and TRP-1?

Conclusion

Uveal melanomas express high levels of immunotherapy candidate proteins, making them suitable for immunotherapeutic approaches.

Supporting Evidence

  • 80% of uveal melanoma lesions displayed 75-100% positive tumor cells for gp100, MART-1, and tyrosinase.
  • Approximately 65% of lesions stained positively for TRP-1.
  • All uveal melanoma lesions were positive for the four markers studied.

Takeaway

This study found that uveal melanoma has a lot of special proteins that can help in cancer treatment, which is good news for patients.

Methodology

The study involved staining tissue samples from 32 primary uveal melanomas and 4 metastases with specific antibodies to detect protein expression.

Limitations

The study included a limited number of metastases, which may not fully represent the expression patterns in all cases.

Participant Demographics

The study included 32 patients with primary uveal melanoma and 4 patients with metastases.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication